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Abstract
Background: The purpose of this study was to test the hypothesis that mast cells that are present
in fibrotic regions of cancer can suppress the growth of tumor cells through an indirect mechanism
involving peri-tumoral fibroblasts.
Methods:  We first immunostained a wide variety of human cancers for the presence of
degranulated mast cells. In a subsequent series of controlled in vitro experiments, we then co-
cultured UACC-812 human breast cancer cells with normal fibroblasts in the presence or absence
of different combinations and doses of mast cell tryptase, mast cell heparin, a lysate of the human
mast cell line HMC-1, and fibroblast growth factor-7 (FGF-7), a powerful, heparin-binding growth
factor for breast epithelial cells.
Results: Degranulating mast cells were localized predominantly in the fibrous tissue of every case
of breast cancer, head and neck cancer, lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and
Hodgkin's disease that we examined. Mast cell tryptase and HMC-1 lysate had no significant effect
on the clonogenic growth of cancer cells co-cultured with fibroblasts. By contrast, mast cell heparin
at multiple doses significantly reduced the size and number of colonies of tumor cells co-cultured
with fibroblasts, especially in the presence of FGF-7. Neither heparin nor FGF-7, individually or in
combination, produced any significant effect on the clonogenic growth of breast cancer cells
cultured without fibroblasts.
Conclusion: Degranulating mast cells are restricted to peri-tumoral fibrous tissue, and mast cell
heparin is a powerful inhibitor of clonogenic growth of tumor cells co-cultured with fibroblasts.
These results may help to explain the well-known ability of heparin to inhibit the growth of primary
and metastatic tumors.
Background
In animal models of carcinogenesis, mast cells have been
shown to play an important role in modulating angiogen-
esis, connective tissue remodeling, blood clotting, and the
growth of tumors [1-3]. Similarly, a number of clinical
investigators, including our laboratory, have documented
the natural presence of mast cells in various human
tumors, including breast cancer and melanoma [4-6]. In
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these studies, the mast cells were described as being pre-
dominantly located in the fibrous tissue stroma adjacent
to the tumor cells rather than within the core of the
tumor.
Collectively, these observations prompted us to speculate
that the mast cells that are naturally present next to
tumors might modulate the growth of the tumor cells
through an indirect mechanism involving the fibroblasts
that are adjacent to the tumor cells. It is now well-estab-
lished, for example, that fibroblasts play a pivotal role in
promoting the growth of many types of cancer cells [7-9]
and that many mast cell granule components exert power-
ful effects on fibroblasts [2,10]. Therefore, in order to test
this hypothesis, we first performed a comprehensive,
immunohistochemical survey of a variety of human
tumors to determine if mast cells are generally restricted to
the fibrous tissue adjacent to tumor cells. To this end,
tumor sections were immunostained for the presence of
mast cell tryptase, a serine protease that is indicates the
presence of intact and degranulated mast cells in tissues.
This marker was selected instead of CD117 or other mark-
ers of intact mast cells because it can specifically identify
intact mast cells as well as regions where mast cells have
disintegrated and released the contents of their granules
into the tissue. Because mast cell granules contain tryptase
that is strongly bound to heparin [11,12], tryptase co-
localizes with heparin in tissue sections and can therefore
serve as an effective surrogate marker for the presence of
heparin in tissues. This property is important because reli-
able immunohistochemical assays to detect the presence
of mast cell heparin in tissue sections are generally not
available.
In the second part of this study, we explored the effects of
two major components of mast cell granules (tryptase and
heparin) and FGF-7 on the clonogenic growth of a human
breast cancer cell line co-cultured with normal human
fibroblasts in a simple co-culture system that we have pre-
viously described in detail [13]. We specifically selected
mast cell tryptase for study because it exerts profound
effects on fibroblast function and proliferation [2,10].
Heparin, a highly sulfated proteoglycan produced exclu-
sively by mast cells, was included in this study because our
previous experiments with mice that were genetically or
enzymatically depleted of mast cell heparin [5,14] have
consistently demonstrated that tumors grow significantly
faster in heparin-depleted mice than in control mice. FGF-
7 was incorporated into our experiments because it is a
powerful, heparin-binding growth factor for breast epithe-
lial cells that is produced by fibroblasts [15-18]. Moreo-
ver, previous studies have clearly demonstrated that
fibroblasts are the predominant source of FGF-7 in malig-
nant breast tissues [18,19].
Here we demonstrate that degranulating mast cells are
restricted almost exclusively to the peri-tumoral fibrous
tissue in human cancers. Moreover, we show that heparin
significantly interferes with the clonogenic growth of
breast cancer cells co-cultured with fibroblasts in the pres-
ence or absence of exogenous FGF-7. These results lead us
to conclude that heparin from mast cells can suppress the
growth of tumor cells through an indirect mechanism
involving the fibroblasts adjacent to the tumor.
Methods
Primary human tumor and normal tissue samples
After obtaining institutional review board approval for
this project, we retrieved the most recent available paraf-
fin blocks from the surgical pathology archives of UCI
Medical Center (Orange, CA) and Long Beach Memorial
Medical Center (Long Beach, CA) for the following types
of tumors: breast cancer (n = 10); head and neck cancer (n
= 10); lung cancer (n = 10), non-Hodgkin's lymphoma (n
= 5); Hodgkin's lymphoma (n = 8); ovarian cancer (n =
10) and their normal tissue counterparts (n = 3 for each
tumor type).
Immunostaining for mast cell tryptase
Representative sections of each tumor and normal tissue
counterpart were immunostained for mast cell tryptase
using a procedure that has been previously described in
detail [5,6] and also histochemically stained with Giemsa
stain to highlight intact mast cells (identifiable by their
dark purple granules). In brief, de-paraffinized tissue sec-
tions of each tumor and normal tissue were first subjected
to antigen retrieval using microwave treatment in citrate
buffer. The tissue sections were then incubated with a
murine monoclonal antibody directed against human
mast cell tryptase (Dako-Cytomation, Carpinteria, Cali-
fornia USA) at a concentration of 10 micrograms/mL for
2 hours. Bound primary antibody was then detected using
the Dako LSAB+ peroxidase kit-universal (Dako-Cytoma-
tion) in accordance with the manufacturer's directions.
The positive control for this antibody was a section of
human breast cancer with extensive infiltration by mast
cells noted on routine histologic examination [6]. Because
virtually all normal tissues contain at least a few mast
cells, the negative controls were serial sections of the same
tissues incubated with isotype-matched, non-immune
IgG from a mouse. The specificity of the immunostaining
was confirmed on two slides by competitive inhibition
with human mast cell tryptase at a concentration of 1
microgram/mL (Sigma-Aldrich, St. Louis, Missouri, USA).
An experienced pathologist then counted the numbers of
mast cells in three representative, non-overlapping, 40 ×
microscopic fields of the peripheral and central regions
(core) of each tumor section. For the normal tissue coun-
terparts, the numbers of mast cells were counted in three,BMC Cancer 2005, 5:121 http://www.biomedcentral.com/1471-2407/5/121
Page 3 of 10
(page number not for citation purposes)
randomly selected and non-overlapping 40 × microscopic
fields of each slide. The means and standard deviations of
mast cell numbers in the two tumor regions and in the
normal tissue counterparts were then calculated and com-
pared statistically, using a two-tailed, unpaired t-test for
significance.
Co-culture assay
The co-culture assay was performed as previously
described [13] In brief, UACC-812 breast cancer cells
(ATCC, Manassas, VA) were seeded at a density of 100
cells per well of a 96-well microtiter plate containing a
confluent monolayer of allegedly normal human fibrob-
lasts (CCD 1068 SK), also from ATCC. The allegedly nor-
mal human fibroblasts were derived from the skin of the
breast from a woman who underwent a mastectomy for
breast cancer. The cells were co-cultured in Eagles mini-
mal essential medium (ATCC) containing 10% fetal calf
serum (Sigma-Aldrich) and penicillin-streptomycin
(ATCC) that was then supplemented on days 1, 4, 7, 10,
and 13 after seeding with human mast cell tryptase
derived from human lung (1, 5, or 10 µgrams/mL; Sigma-
Aldrich, St. Louis, MO), or purified porcine intestinal
derived heparin, high molecular weight type (0.1,1.0,
10.0 and 100 units/mL; Sigma-Aldrich); and/or human
fibroblast growth factor-7 (100 ng/mL;Chemicon Interna-
tional, Temecula, CA). It should be noted that the lung-
derived tryptase used in these experiments contained 0.05
mM heparin, but the final concentration of heparin in the
tryptase solution used in our experiments was approxi-
mately 20-fold less than the lowest concentrations of por-
cine heparin used alone. On day 14, the cells were fixed in
situ by incubating the wells with ice-cold methanol for 10
minutes. The cells were then stained in situ with 0.1%
toluidine blue, and we used routine light microscopy to
count the numbers of colonies of tumor cells containing
10 or more tumor cells in each well. Each assay was per-
formed in triplicate, and the means and standard devia-
tions for the numbers of colonies in each treatment and
control group were then calculated and compared using a
two-tailed unpaired t-test for significance.
The positive control for the assay consisted of identical
numbers of tumor cells co-cultured on a monolayer of
fibroblasts without any additional supplements to the
growth medium. In order to determine if any effects that
we observed were attributable to the fibroblasts, we also
performed the clonogenic assay as described above, but in
the absence of a monolayer of fibroblasts.
For comparative purposes, we also performed the co-cul-
ture assay in the presence of 50 microliters of lysate equiv-
alent to 106 HMC-1 cells/mL. The HMC-1 cell line is a
human mast cell line derived from a patient with mast cell
leukemia [20] and was the generous gift of Dr. J.H. Butter-
field from the Mayo Clinic (Rochester, Minnesota, USA).
It expresses many of the markers and cytoplasmic compo-
nents of normal mast cells [20] and was cultured under
conditions that have been previously described [20]. The
HMC-1 lysate was produced by a procedure described by
Huttunen et al [21]. To confirm the presence of heparin in
the HMC-1 cells, we stained cytopreparations of the cul-
tured cells for 30 seconds with 0.1% toluidine blue, a met-
achromatic dye that binds strongly to heparin and
produces an intense blue color in the granules of normal
mast cells [11].
Measurement of tumor colony size
Digital images of 10–50 representative colonies of tumor
cells in each well were acquired at 40 × magnification with
a Nikon Eclipse E600 microscope equipped with a Spot II
digital camera (Diagnostic Instruments, Sterling Heights,
MI). Because some treatments resulted in far fewer colo-
nies (see below) than the control group, the numbers of
colonies that were analyzed among the different treat-
ment groups varied from group to group. The digital
images were then analyzed using a digital tool (Image Pro
Plus version 4.5, Media Cybernetics, Inc., Silver Spring,
MD) to outline the area of the tumor cell colony in each
image. The area in each colony was electronically inte-
grated, and we plotted the distribution of areas as a fre-
quency histogram for each treatment and control group.
The data were then analyzed statistically using the Mann-
Whitney U-test for two samples and ranked observations,
not paired.
Detection of FGF-7 in cultured human fibroblasts
A number of other investigators have previously docu-
mented with Western blotting and in situ hybridization
that fibroblasts secrete FGF-7 and are the predominant
source of FGF-7 in normal tissues and in breast cancers
[18,19]. In order to confirm that the monolayer of fibrob-
lasts that was used in our experiments was also producing
FGF-7, we first immunostained the fibroblasts in situ with
a monoclonal antibody directed against FGF-7 (Chemi-
con International), using a procedure that we have previ-
ously described in detail [13]. The negative controls
consisted of an irrelevant monoclonal antibody or block-
ing buffer alone. As an additional confirmation for the
production of FGF-7 by the fibroblasts, we analyzed the
gene expression profile of the cultured fibroblasts, using a
DNA microarray as previously described by us [13].
In order to provide additional confirmation of the pres-
ence of FGF-7 in the fibroblasts, we performed Western
blotting of an immunoprecipitate of cultured fibroblasts.
In brief, the 1068SK cells were lysed using RIPA Lysis
Buffer (Upstate Biochemicals, Lake Placid, NY USA) sup-
plemented with 1 mM PMSF. The cell lysates was then
incubated with 0.3 ug/ml anti-FGF7 (Chemicon) for 1BMC Cancer 2005, 5:121 http://www.biomedcentral.com/1471-2407/5/121
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hour then bound to Protein G beads (Sigma) for 1 hour.
Beads were washed and spun down at 1,400 rpm for 1
minute in a microcentrifuge. Pelleted beads were boiled
for 10 minutes at 95°C in sample buffer, centrifuged at
top speed for 5 minutes and the resulting supernatant was
collected for separation by SDS-PAGE on a 12% separat-
ing gel. Proteins were transferred to PVDF membrane
(BioRad, Hercules, CA USA), incubated with rabbit anti-
human KGF primary antibody (Chemicon) then with
HRP conjugated goat anti-rabbit secondary antibody
(BioRad), and visualized by Opti-4CN Detection Kit (Bio-
Rad). The negative control consisted of a lysate of a
murine melanoma cell line, B16. The positive control
consisted of human FGF-7 (Chemicon) as described
above.
Results
Mast cells in fibrotic regions of tumors
A summary of the results of the immunostaining for mast
cell tryptase is provided in Table 1. In all of the human
tumors that we examined, mast cell tryptase and intact
mast cells were located predominantly at the edges of the
tumors and within the fibrous stroma next to tumors (Fig-
ure 1a–e). Notably, the mast cell infiltration was signifi-
cantly greater in the tumors than in the normal tissue
counterparts for almost all of the tumor types that we
examined. Only the Hodgkin's lymphomas and non-
Hodgkin's lymphomas consistently had substantial
amounts of tryptase detectable within the core of the
tumors, but even in these tumors, there were more mast
cells at the edges of the tumor and in the fibrous stroma
subdividing the tumor mass (Table 1 and Figure 1f). The
Giemsa stain confirmed that intact mast cells were almost
exclusively found embedded within the fibrous stroma
within tumors (Figure 1d).
Reduction of clonogenic growth of breast cancer cells by 
heparin
The results of a representative clonogenic assay performed
in triplicate with 1 unit/mL of heparin are presented in
Figure 2. The experiment was repeated three times, with
similar results. The consistent and notable finding was
that this low dose of heparin significantly decreased the
number of colonies of tumor cells in the co-culture assay
with fibroblasts. The lowest concentration of heparin (0.1
units/mL) produced no detectable effect (average number
of colonies = 45 ± 6, n = 3), while the higher doses of
heparin (10 and 100 units/mL) produced effects very sim-
ilar to 1 unit/mL (data not separately shown).
FGF-7 slightly increased the number of colonies, but this
effect was neutralized by heparin. Tryptase at all of the
concentrations that we tested produced no significant
change in the numbers or sizes of tumor cell colonies in
the co-culture assay (data not shown), despite the pres-
ence of small amounts of heparin in the tryptase solution.
When the clonogenic assay was performed in the absence
of fibroblasts, an average of only 23 ± 4 (n = 4) colonies
were formed. Neither heparin nor FGF-7, individually (18
± 5 colonies, n = 3) or in combination (20 ± 7 colonies, n
= 3) significantly changed the clonogenic growth of breast
cancer cells cultured without fibroblasts.
Importantly, the lysate of HMC-1 cells produced no sig-
nificant effect on the clonogenic growth of the breast can-
cer cells in the co-culture assay (average number of
colonies = 24 ± 4, n = 3). A toluidine blue stain of the cul-
tured mast cell line revealed only weak staining of small
numbers of intracytoplasmic granules (Figure 3) com-
pared to the intense staining that is normally seen in mast
cell granules [11,14]. This result suggests that the HMC-1
cell line grown in our laboratory produced only small
amounts of heparin.
Table 1: Comparison of mast cell numbers in tumors and corresponding normal tissues.
Mean Numbers of Mast Cells/40 × Field (± 1 standard deviation)
Peri-tumoral tissue Core of tumor Normal tissue
Breast (n = 10) 4.9 ± 1.1 0.3 ± 0.3* 1.2 ± 0.9**
Head & neck (n = 10) 6.7 ± 3.6 0.5 ± 0.3* 2.8 ± 2.1**
Ovarian (n = 10) 3.0 ± 0.8 0.7 ± 0.6* 0.9 ± 0.8**
Lung (n = 10) 4.4 ± 1.9 1.0 ± 0.3* 2.5 ± 0.6 **
Non-Hodgkins (n = 5) 2.1 ± 1.0 1.8 ± 0.5 NS 1.0 ± 0.5 NS
Hodgkin's (n = 8) 4.3 ± 1.3 1.9 ± 0.8* 1.0 ± 0.5**
*p value < 0.05, comparing mean numbers of mast cells in core of tumor versus per-tumoral regions.
** p value < 0.05, comparing mean numbers of mast cells in normal tissue counterparts (n = 3) to peri-tumoral tissue.BMC Cancer 2005, 5:121 http://www.biomedcentral.com/1471-2407/5/121
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Representative photomicrographs of mast cell infiltration in human head and neck cancer (1a), lung cancer (1b, c), ovarian can- cer (1d, e), and Hodgkin's disease (1f) Figure 1
Representative photomicrographs of mast cell infiltration in human head and neck cancer (1a), lung cancer 
(1b, c), ovarian cancer (1d, e), and Hodgkin's disease (1f). In Figures a-c, e and f, the sections were immunostained for 
mast cell tryptase and revealed extensive evidence of mast cell degranulation (brown stain) in the fibrous tissue adjacent to 
nests of tumor cells and blood vessels. A Giemsa stain (1d) confirmed the presence of intact mast cells with dense purple gran-
ules embedded within fibrous stroma between nests of tumor cells. Hematoxylin counterstain (all figures, except 1d).BMC Cancer 2005, 5:121 http://www.biomedcentral.com/1471-2407/5/121
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Reduction of size of tumor cell colonies by heparin
Visual microscopic examination of the tumor cell colonies
in the clonogenic co-culture assay suggested that heparin
produced a striking reduction in the size of the tumor cell
colonies (Figure 4). This effect appeared to be particularly
pronounced when heparin was added to co-cultures sup-
plemented with FGF-7 that, by itself, markedly increased
the size of the colonies (Figures 4c, d vs 4e). A statistical
analysis of the distribution of colony sizes confirmed that
heparin significantly reduced the size of the tumor cell
colonies relative to the control or to FGF-7 treatment (Fig-
ure 5).
FGF-7 on membrane of cultured fibroblasts
Immunostaining studies confirmed that the fibroblasts
expressed abundant FGF-7 on their cell membranes (Fig-
ure 4f). The negative control antibody and blocking buffer
yielded no staining of the fibroblasts. The DNA microar-
ray studies performed in triplicate indicated the presence
of abundant mRNA coding for FGF-7 in the cultured
fibroblasts (mean signal intensity 3940).
Western blotting (Figure 6) confirmed that our anti-FGF-
7 antibody specifically recognized FGF-7 (lane 3) and not
an immunoprecipitate of a negative control cell line (lane
2). The immunoprecipitate of the fibroblasts (lane 1)
yielded a band at approximately 66 kD, similar to the
results described by Palmieri et al [18]. The higher molec-
ular weight of the FGF-7 in the immunoprecipitate of
fibroblasts is probably attributable to the presence of
tightly bound heparan sulfate from the cell membrane, as
described by Palmieri et al [18].
Discussion
Our immunohistochemical studies have demonstrated
that degranulating mast cells are located primarily in the
peri-tumoral fibrous tissue in a wide variety of human
cancers. Moreover, we have shown that heparin (a prote-
oglycan that is produced exclusively by mast cells) inhib-
its the clonogenic growth of human breast cancer cells co-
cultured with normal fibroblasts but not tumor cells cul-
tured alone. Significantly, the lysate of a human mast cell
line, HMC-1, did not have any detectable effect on the clo-
nogenic growth of the co-cultured tumor cells. We believe
that this is probably due to the low levels of heparin in
these cells, but we cannot exclude the possibility that
some other component of mast cells may have neutralized
the inhibitory effect of heparin. Similarly, various doses of
tryptase had no effect on clonogenic growth. Taken
together, these results provide strong evidence that mast
cells can suppress the growth of tumor cells through an
indirect mechanism that involves heparin and fibroblasts
adjacent to the tumor cells.
Results of clonogenic assay of breast cancer cells co-cultured  with fibroblasts in the presence or absence of heparin and/or  FGF-7 Figure 2
Results of clonogenic assay of breast cancer cells co-
cultured with fibroblasts in the presence or absence 
of heparin and/or FGF-7. After 14 days of co-culture, the 
numbers of colonies containing 10 or more tumor cells were 
counted and averaged. Heparin significantly reduced the 
numbers of tumor cell colonies in the presence or absence of 
exogenous FGF-7. When the tumor cells were cultured in 
the absence of fibroblasts, only an average of 24 colonies 
were formed, and the heparin had no significant effect on the 
numbers of colonies.
Toluidine blue stain of cytopreparation of HMC-1 cells Figure 3
Toluidine blue stain of cytopreparation of HMC-1 
cells. Relatively few blue granules were detected in the cul-
tured human mast cell line, suggesting that the cultured mast 
cell line produced only small amounts of heparin.
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This conclusion is consistent with our previous reports
that depletion of endogenous heparin results in acceler-
ated tumor growth in mice [5,14]. In specific, we previ-
ously showed that syngeneic tumor cells implanted into
NDST-2 knockout mice grew faster than tumor cells
implanted into wild-type mice that synthesized normal
heparin [5,14]. NDST-2 knockout mice are unable to syn-
thesize mast cell heparin and express abnormal mast cells
with severely reduced amounts of histamine and mast cell
proteases [11], probably because highly anionic heparin is
required to stabilize the cationic compounds histamine,
tryptase and chymase. Moreover, enzymatic depletion of
mast cell heparin by injection of heparinase enzyme into
tumor implants also accelerated tumor growth [14] and
increased blood clotting within the tumors. Based on the
results of the current study, we now propose that the accel-
erated tumor growth that we observed in heparin-
depleted mice could be attributable, at least in part, to the
absence of heparin-mediated inhibition of the growth-
promoting interaction between fibroblasts and adjacent
tumor cells.
Our findings are important because they may help to
explain the well known ability of heparin and its deriva-
tives to inhibit the growth of primary and metastatic
tumors in various animal models and in humans with
cancer [22-29]. Although the exact mechanism of this
anti-tumor effect mediated by heparin remains uncertain,
a number of possible explanations [30] have been pro-
posed, including inhibition of thrombin and fibrin for-
mation, immune system modulation, blockade of tumor
cell adhesion to platelets, inhibition of angiogenesis, and
Photomicrographs of tumor cell colonies (3a-e) and fibroblasts immunostained for FGF-7 (3f) Figure 4
Photomicrographs of tumor cell colonies (3a-e) and fibroblasts immunostained for FGF-7 (3f). In the absence of 
heparin, breast cancer cells co-cultured on a monolayer of fibroblasts generally produced irregularly shaped large clusters of 
tumor cells (3a). When heparin was added to the co-culture system, the tumor cells generally formed compact clusters (3b). 
FGF-7 added to the co-culture system resulted in large glandular-like structures composed of a peripheral rim of compact 
tumor cells and a central core of plate-like epithelial cells (3c, d). Heparin completely reversed the effects of FGF-7 and pro-
duced small compact clusters of darkly staining tumor cells (3e). Immunostaining for FGF-7 (3f) confirmed the abundant pres-
ence of FGF-7 (pink stain) on the membrane of the fibroblasts. Toluidine blue stain (3a-e).BMC Cancer 2005, 5:121 http://www.biomedcentral.com/1471-2407/5/121
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functional inhibition of selectin-mediated cell-cell inter-
actions leading to metastasis [31]. Heparins can also
directly inhibit proliferation of various normal cell types,
including smooth muscle cells and epithelial cells
[reviewed in [32]]. Under some conditions, however,
heparin actually stimulated the growth of epithelial cells
[21]. On the other hand, only a few studies have directly
evaluated the effects of heparin on the proliferation of
cancer cells [also reviewed in [32]], and the results of these
studies are generally inconclusive. Therefore, we propose
that another possible mechanism for the anti-tumor effect
of heparin observed in vivo may be the disruption of the
critical, growth- promoting interactions that are known to
occur between tumor cells and adjacent fibroblasts [7-9].
Although this study was not designed to explore the
molecular mechanism of how heparin disrupts the inter-
action between fibroblasts and tumor cells, one possible
explanation comes immediately to mind. Based on our
findings with FGF-7, we speculate that heparin may dis-
rupt the interaction of heparin-binding growth factors
such as FGF-7 with heparan sulfate proteoglycans that are
produced by fibroblasts and that act as essential co-factors
for the growth factors. This explanation is consistent with
our recent observation that optimal clonogenic growth of
breast cancer cells in vitro requires direct physical contact
between fibroblasts and breast cancer cells [13]. Moreo-
ver, previous reports from other laboratories have con-
firmed that human breast cancer cells are generally in
close contact with fibroblasts that express abundant FGF-
7 [18,19]. Finally, various heparan sulfate proteoglycans
such as syndecan-1 and glypican are known to be
expressed by stromal cells in cancer and to modulate the
mitogenic effects of multiple heparin-binding growth fac-
tors [33,34]. In this regard, it is especially notable that
heparin had no effect on FGF-7-mediated stimulation of
mammary epithelial cells grown in a collagen gel matrix
in the absence of fibroblasts [6]. Hence, it is reasonable to
propose that heparin might interfere with the natural
binding of heparin-binding growth factors to heparan sul-
fate proteoglycans produced by fibroblasts. Clearly, addi-
tional studies will be needed to test this hypothesis.
Distribution of tumor cell colony sizes Figure 5
Distribution of tumor cell colony sizes. The average 
sizes of the tumor cell colonies as measured by digital image 
analysis were 16,428 pixels for the control; 9917 pixels for 
heparin alone; 35,760 pixels for FGF-7 alone; and 5551 pixels 
for the cells treated with heparin and FGF-7. Heparin signifi-
cantly reduced the distribution of colony sizes in the pres-
ence or absence or FGF-7 as determined by a Mann-Whitney 
U-test.
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Western blot of FGF-7 in immunoprecipitate of fibroblasts Figure 6
Western blot of FGF-7 in immunoprecipitate of 
fibroblasts. The polyclonal antibody recognized the positive 
control (approximately 22 kD; human FGF-7, lane 3) and did 
not bind to an immunoprecipitate of an irrelevant cell line (IP 
negative control, lane 2). The immunoprecipitate of the 
fibroblasts in lane 1 yielded a band at approximately 66 kD, 
which we attributed possibly to binding of FGF-7 to a 
heparan sulfate proteoglycan in the cell membrane.BMC Cancer 2005, 5:121 http://www.biomedcentral.com/1471-2407/5/121
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The possible biological and clinical significance of our in
vitro experimental findings with regard to the naturally
occurring mast cells that we observed around tumors
remain speculative. Nevertheless, our observation that
mast cells are abundantly present within the fibrous
regions of tumors raises the intriguing possibility that a
growth inhibitory mechanism similar to the one that we
observed in our in vitro studies could also be naturally
operative within tumors in vivo. The possible connection
between our in vitro experiments and naturally occurring
tumors is further strengthened by the reports from other
laboratories that peri-tumoral fibroblasts express abun-
dant FGF-7 [18,19] and that mast cell tryptase is inti-
mately associated with the concurrent presence of heparin
[11,12].
We acknowledge, however, that this possibility seems to
be at odds with the accumulating evidence that mast cells
promote rather than inhibit tumor growth [1,2]. In this
regard, it should be emphasized that mast cell granules
contain numerous biologically active compounds in addi-
tion to heparin, such as histamine, tryptase, and chymase.
Some of these mast cell compounds and metabolites are
likely to have significant effects on fibroblasts that remain
to be defined. In addition, a number of other mediators
from fibroblasts and mast cells could potentially influ-
ence tumor growth through a variety of mechanisms such
as cyclooxygenase metabolites, heparanases, etc. The net
effect on tumor growth, therefore, is likely to be the result
of multiple complex interactions between the various
components of mast cell granules and adjacent stromal
cells such as vascular endothelium and fibroblasts.
Indeed, our immunohistochemical studies also demon-
strated close proximity of mast cells to peri-tumoral blood
vessels as well as to fibroblasts. Consequently, it is entirely
conceivable that the stimulatory effects of mast cells on
angiogenesis or fibroblasts or other functions within
tumors might outweigh the inhibitory effects mediated by
mast cell heparin and fibroblasts.
Conclusion
Multiple independent lines of evidence strongly suggest
that heparin from mast cells can suppress tumor cell
growth through an indirect mechanism involving
adjacent fibroblasts. The evidence includes the localiza-
tion of mast cells to fibrous regions of tumors, the ability
of heparin to inhibit tumor growth in vivo and in vitro in
the presence of fibroblasts, and the accelerated growth of
tumors in mice that were genetically or enzymatically
depleted of heparin. Thus, we propose that further molec-
ular analysis of the interaction between fibroblasts and
heparin is warranted and may lead to improved insights
into how heparin mediates its anti-tumor effect and, ulti-
mately, to improved anti-tumor therapies.
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